Abstract TP68: Nina Campbell MSN BSN RN

Nina campbell,ALEXANDRA LINDNER

DOI: https://doi.org/10.1161/str.55.suppl_1.tp68

IF: 10.17

2024-02-01

Stroke

Abstract:Many of the American Heart Association’s Get with the Guidelines metrics for stroke are medication-related, including appropriate utilization of antithrombotics, statins, and anticoagulation. Furthermore, for the subpopulation of patients with type 2 diabetes, an antihyperglycemic medication with proven cardiovascular benefit is indicated. Abstraction to the American Heart Association Get with the Guidelines has clear but complex guidelines on criteria for meeting these metrics. Our goal was to improve adherence to the guidelines via pharmacist assessment, discussion, and documentation. Prior to December 2022, clinical pharmacists had been reviewing the use of antithrombotics, statins, and anticoagulation in stroke patients and reaching out to the provider with concerns. However, they were not yet reviewing the use of antihyperglycemic medications with proven cardiovascular benefit nor documenting assessments/rationale in the patient’s chart. In December 2022, pharmacists started evaluating antihyperglycemic medications with proven CVD benefits in addition to the above, with assessments taking place Monday through Friday. The pharmacist would reach out to the provider when necessary and also document rationale for appropriate avoidance of usual recommended therapy, if indicated. The most notable intervention was the creation of pre-formatted note with the various specific ways to meet each medication-related metric in accordance with Get with the Guidelines abstraction criteria. Baseline data from January to November 2022 indicated good adherence to the stroke metrics involving the use of antithrombotics, statins, and anticoagulation that pharmacy was already following at that time, ranging from 97.7-100% adherence. However, the metric of addressing an antihyperglycemic medication with proven CVD benefit was only met 47.1% of the time. After the above intervention, data collected from March to July of 2023 demonstrated a stable effect on the metrics that were already above goal, ranging 96.5% to 100%, but there was a significant increase in adherence to the antihyperglycemic medication with proven CVD benefit, which went from 47.1% to 83.3%.

peripheral vascular disease,clinical neurology